Search Results

Keywords: epidiolex

GW Pharma Could Win FDA Approval in Early 2016

August 5, 2015 · Updated August 6, 2015

GW Pharma appears poised to enter the United States cannabis market. The British company reportedly could get clearance from the U.S. Food and Drug Administration for a CBD-based product by early next year.

Read More

GW Pharmaceuticals Added to Nasdaq Biotech Index

December 23, 2014 · Updated April 7, 2020

GW Pharmaceuticals, a United Kingdom-based company that develops CBD-rich treatments, has been added to the Nasdaq Biotechnology Index (NBI). The NBI tracks the performance of a set of securities traded on the exchange that are classified as biotech or pharmaceutical companies. GW Pharmaceuticals is the developer of Sativex, a cannabis-based drug that is approved in […]

Read More

UK Company Raising $148M to Advance CBD Drug

June 20, 2014 · Updated July 25, 2014

British drug maker GW Pharmaceuticals plans to raise $148 million from U.S. investors to advance an epilepsy drug that uses cannabidiol (CBD). The company will sell 1.7 million American Depository Shares on the Nasdaq – where it trades under the symbol GWPH – priced at $86.83 each. The drug, called Epidiolex, contains cannabidiol oil extracted […]

Read More